Shares up as much as 63 pct in heavy-volume trade (Adds conference call details; updates stock movement) Aug 25 (Reuters) - Somaxon Pharmaceuticals Inc SOMX.O cleared the path to get its lead insomnia drug Silenor in U.S. …
p><location value="LU/us.ca.sandgo" idsrc="xmltag.org">SAN DIEGO</location>--(BUSINESS WIRE)-- <org …
Translation: The upward trend remains intact but there's some disquieting underlying technical deterioration that we must take note ... the economy up to full and steady growth. As for why the stock market is rallying on this lukewarm …
Somaxon Pharmaceuticals Inc. SOMX.O is hoping to file an application with U.S. regulators ... Eli Lilly shares closed down 14 cents at $51.63 on the New York Stock Exchange. (Additional reporting by Bill Berkrot in New York) Our …
Crew Group, Inc. (NYSE: JCG), Netezza Corporation (NYSE: NZ), 3PAR, Inc. (NYSE: PAR), Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), SunPower Corporation (NASDAQ: SPWRA) and Sterling Financial Corp. (NASDAQ: STSA). …
In addition, Zacks Equity Research provides analysis on Mylan Inc. (MYL), Somaxon Pharmaceutical, Inc. (SOMX) and …
10/07 SkyWest, Inc. $SKYW Shares Sold by New York State Common Retirement Fund 10/07 Reviewing SkyWest …
The FDA's approval of Somaxon (SOMX)'s new sleeping pill, Silenor, has come at just the wrong time -- just as cheap, generic versions of Ambien CR come on to the market-- yet some still believe the drug could rack up nearly $1 billion in …
Vivendi VIVHY downgraded to underperform from neutral at Exane BNP Paribas. Quicksilver KWK downgraded to Neutral from Buy at UBS on reduced natural gas forecasts and funding concerns. Price target lowered to $11 from $13. Darden …
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company ... and the impact of any …